^
    1d
    FORTITUDE-301: A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (clinicaltrials.gov)
    P1/2, N=260, Completed, Amgen | Active, not recruiting --> Completed
    Trial completion • Pan tumor
    |
    FGFR2 overexpression
    |
    bemarituzumab (AMG 552)
    1d
    Study of the Effects of Pre-surgical Aerobic Exercise on Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=60, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    1d
    Partial Breast Proton Therapy for Early Stage Breast Cancer (clinicaltrials.gov)
    P=N/A, N=150, Active, not recruiting, Loma Linda University | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    1d
    Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing (clinicaltrials.gov)
    P=N/A, N=180, Not yet recruiting, Unity Health Toronto
    New trial
    1d
    FEGALA: Impact on Quality of Life and Health of the CONTINUUM+ CONNECT Remote Monitoring Solution (clinicaltrials.gov)
    P=N/A, N=411, Completed, Centre Paul Strauss | Recruiting --> Completed | Trial completion date: Feb 2025 --> Jan 2026 | Trial primary completion date: Nov 2024 --> Nov 2025
    Trial completion • Trial completion date • Trial primary completion date • HEOR
    1d
    IMACT: Inspiratory Muscle Training for Breast Cancer Patients on Chemotherapy (clinicaltrials.gov)
    P=N/A, N=58, Recruiting, Ohio State University Comprehensive Cancer Center
    New trial
    1d
    Sexual Well-being of Women Undergoing Mastectomy and Reconstruction (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, European Institute of Oncology | Not yet recruiting --> Recruiting
    Enrollment open
    1d
    PSID: Precision Supplemental Imaging in Women With Dense Breasts (clinicaltrials.gov)
    P=N/A, N=78, Not yet recruiting, Washington University School of Medicine | Trial completion date: Dec 2028 --> Mar 2029 | Initiation date: Dec 2025 --> Mar 2026 | Trial primary completion date: Dec 2028 --> Mar 2029
    Trial completion date • Trial initiation date • Trial primary completion date
    1d
    Assessment of Safety, Tolerability and PK Profile of MSP008-22 in Patients With Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=7, Completed, Godavari Biorefineries Limited | Not yet recruiting --> Completed | N=27 --> 7 | Trial completion date: Jan 2023 --> Jan 2026 | Trial primary completion date: Dec 2022 --> Jan 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    1d
    A Phase Ⅲ Randomized Clinical Study and Real World Study of Postoperative Regional Nodal Radiotherapy in Intermediate-risk Breast Cancer (clinicaltrials.gov)
    P3, N=3142, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P3 trial • Real-world evidence
    1d
    CURB: Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung (clinicaltrials.gov)
    P2, N=107, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK rearrangement • ROS1 rearrangement